REVIEW ARTICLE
A Focused Review on Emerging SARS-Cov-2 Variants
Anagha Renjitha1, Malavika Jayaram1, #, Ayisha A. Jabbar1, #, Aparna B. Murukan1, #, Haripriya Haridasan1, #, Akshara Prijikumar1, #, Sneha Baiju1, #, Adrial Ann Nixon1, #, Nihal Najeeb1, #, Ponnambil Anantha Krishnan1, #, Sunu Rodriguez1, #, Bipin G. Nair1, Arya Aloor1, Renuka Suravajhala1, Prashanth Suravajhala1, *
Article Information
Identifiers and Pagination:
Year: 2023Volume: 3
E-location ID: e266695872304120
Publisher ID: e266695872304120
DOI: 10.2174/26669587-v3-2305300-2022-48
Article History:
Received Date: 19/11/2022Revision Received Date: 13/02/2023
Acceptance Date: 22/03/2023
Electronic publication date: 06/06/2023
Collection year: 2023

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Over the past 33 months, 10 SARS-CoV-2 mutant variants have evolved. Among them, very few were infectious, while the rest were not that rampantly infectious. As COVID-19 has been the century’s most destructive pandemic, and as the variants of concern and significance are heralding nature, there is an inherent need to bring collaborative convergence among scientists to combat future pandemics such as COVID-19. A question remains whether these emerging variants could allow us to define the advent of pathogenesis and whether or not we are prepared. In this review, we give a gist of variants that could be associated with the recombination events concerned with SAR-CoV-2 that have an impact on the immune response in the human body.